Kathy Flanagan
Psychiatry · Houston, TXNPI 1073662714
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $352,210 of the $443,470 with a category attached, or 79.4%. AbbVie accounts for 98.1% of it on its own, with 22 other manufacturers making up the rest. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 846 payments — averaging $524.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$435K
- Vanda Pharmaceuticals Inc.$5K
- Teva Pharmaceuticals USA, Inc.$518
- GSK$345
- AstraZeneca$341
- Inspire Medical Systems, Inc.$277
- plus $2K from 17 others
What the payments were for
- Consulting fees$4,5001%
- Speaking & faculty fees$352,21079%
- Travel & lodging$71,84716%
- Food & beverage$14,7653%
- Education$1480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 797 | $435,181 |
| Vanda Pharmaceuticals Inc. | 4 | $5,042 |
| Teva Pharmaceuticals USA, Inc. | 9 | $518 |
| GSK | 4 | $345 |
| AstraZeneca(2 entities) | 4 | $341 |
| Inspire Medical Systems, Inc. | 3 | $277 |
| Johnson & Johnson | 2 | $238 |
| Neurocrine Biosciences, Inc. | 2 | $234 |
| Novo Nordisk | 2 | $192 |
| Sanofi | 1 | $131 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Abbott | 1 | $122 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| Axsome Therapeutics, Inc. | 1 | $109 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $100 |
| Sunovion Pharmaceuticals Inc. | 1 | $96 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Ironshore Pharmaceuticals Inc. | 1 | $27 |
| Alkermes, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$443,470 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vilazodone Hcl | 15 | $2,653 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 11 | $1,893 |
| Escitalopram Oxalate | 28 | $422 |
| Aripiprazole | 16 | $306 |
| Lamotrigine | 14 | $191 |
| Alprazolam | 18 | $81 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Rayan Al JurdiHouston$359K
- Prashant GajwaniHouston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.